Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Worldwide Revenue ($M) ($M)
Legacy standalone subsegment reported through Q4 2025.
Latest, FY2025
517
Period ended Dec 31, 2025
Change on a year earlier
-0.8%
521 in FY2024
History
11 years
Since FY2015
Sources
10
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Worldwide Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 517 | -0.8% | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 521 | -9.2% | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 574 | -42.3% | SEC Filing (0001628280-25-002092) ↗ |
| FY2022 | Dec 31, 2022 | 995 | -30.3% | SEC Filing (0001628280-24-002009) ↗ |
| FY2021 | Dec 31, 2021 | 1,427 | -0.8% | SEC Filing (0001628280-23-001516) ↗ |
| FY2020 | Dec 31, 2020 | 1,438 | +225.3% | SEC Filing (0001104659-21-007942) ↗ |
| FY2019 | Dec 31, 2019 | 442 | -8.7% | SEC Filing (0001104659-20-005717) ↗ |
| FY2018 | Dec 31, 2018 | 484 | +4.5% | SEC Filing (0001104659-19-002848) ↗ |
| FY2017 | Dec 31, 2017 | 463 | +1.5% | SEC Filing (0001104659-18-003691) ↗ |
| FY2016 | Dec 31, 2016 | 456 | -2.1% | SEC Filing (0001104659-17-003920) ↗ |
| FY2015 | Dec 31, 2015 | 466 | – | SEC Filing (0001104659-16-091861) ↗ |
Breakdown
What makes up molecular diagnostics (legacy standalone subsegment through fy2025q4 — alinity m) — worldwide revenue ($m)
- Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Organic / Comparable Sales Growth (%)-1.2% · FY2025
- Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Reported Sales Growth (%)-0.7% · FY2025
- Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Foreign Exchange Impact on Sales Growth (%)0.5% · FY2025
- Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — U.S. Revenue ($M)150 · FY2025
- Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — International Revenue ($M)367 · FY2025
- Molecular Diagnostics — Organic Sales Growth Excl. COVID-19 Testing (%)-3.2% · FY2024
- Molecular Diagnostics — COVID-19 Testing Sales ($M)12 · FY2024
Cite this data
StockData. (2026). Abbott Laboratories Molecular Diagnostics (Legacy Standalone Subsegment through FY2025Q4 — Alinity m) — Worldwide Revenue ($M) ($M), annual FY2015–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/dx-mol-leg-rev-ww
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.